Our next chapter: €25M growth investment to scale patient access worldwide

Why this moment matters

When I joined myTomorrows in 2017, I had been working as a physician at a top-tier cancer centre Netherlands. Treating patients with complex and often terminal cancer diagnoses, I saw the profound impact on patients and their families. At the same time, I saw how difficult it was for patients and their physicians to navigate the maze of treatment options. The process was often fragmented, time-sensitive, and overwhelming, especially when standard therapies were no longer effective.

Today marks a huge milestone in our journey. I am incredibly proud to share that we have closed a €25 million growth equity round with Avego Healthcare Capital to scale our work and take the next step forward.

Over 300 million patients worldwide still lack available treatments, despite the 10,000 therapies in development or not yet approved¹. Disconnected systems, regulatory complexity, and geographic disparities continue to prevent patients and physicians from finding and benefiting from promising therapies.

myTomorrows exists to bridge this gap. We have already made significant progress, but with this investment, and the expertise and network of our new partner, we are ready to build a future where access to all treatments is fair, fast, and truly global.

Where did we come from?

Our origin story

myTomorrows began with a personal story. Our founder, Ronald Brus MD, spent years leading drug development programs at some of the world’s top pharmaceutical companies. But when his father faced a cancer diagnosis, Ronald experienced firsthand just how difficult it was to access emerging treatments.

Despite his medical background and vast industry connections, navigating access to investigational treatments proved confusing, slow, and in some cases often impossible. This experience led Ronald to realize that if it was this difficult for him, it must be almost insurmountable for others.

That realization inspired him to create myTomorrows — a platform which would improve access to tomorrow’s medicines for patients that need them today.

Our evolution from distribution partner to global access platform

In its early years, myTomorrows built the infrastructure and partnerships to distribute medicines through paid-for expanded access programs. But in 2020, it became clear that we needed to go further.

Listening to patients, caregivers, physicians, and our pharma partners made it clear: we needed to bridge the gap to all pre-approval treatments, across all regulatory pathways.

With a refined focus, we evolved our business model to include:

• Free-of-charge expanded access management including real-world data collection.
• Patient recruitment that helps companies to find, pre-screen and enroll the right patients faster.

This was a turning point for myTomorrows. To support the transformation, we built an advanced technology platform that shifted our role from a distribution partner, into a global access solution —connecting patients, caregivers, and physicians to every available pre-approval treatment and helping bring new therapies to market faster.

Where are we now?

Our mission & vision

In today’s world, where technology is transforming many aspects of healthcare, we hold the keys to reimagine how patients access emerging therapies.

At myTomorrows, we believe that unlocking earlier and better access requires more than just technology. It takes a comprehensive multi-stakeholder solution, uniting the healthcare ecosystem to create a more connected, transparent and holistic view of patient access. We deliver this via a blend of intelligent digital solutions and personalized, high-touch services. Together, these strengths empower patients, physicians, and BioPharma partners alike, championing every stakeholder across the healthcare industry.

We believe in a world where every breakthrough has a clear access path to patients in need.

Our current services & capabilities

• A unified access hub: Our multi-stakeholder platform brings together clinical trials and expanded access programs in one place.
• Smarter trial recruitment: AI-powered matching reduces pre-screening time by up to 90%, giving physicians and trial sites quicker visibility of patient eligibility.
• Compliance-ready access pathways: We provide transparent information on relevant trials and, where appropriate, expanded access programs. Seamless request initiation ensures every access route is compliant and efficient.
• Human expertise: Our multilingual patient navigation team provides personalized support across global time zones.
• Trusted BioPharma partner: Leading companies rely on us for faster trial recruitment, expanded access management, and real-world data that informs regulatory submissions.

Our partnerships & impact

Over the past years, we have built global networks to reach as many patients as possible. To date, we have enrolled over 16,900 patients, supported 2,800+ physicians and connected with over 340 sites. We collaborate with more than 60 leading biopharma companies and maintain deep ties with patient communities, supported by advocacy groups. With a headquarters in Amsterdam, offices in New York and an operational hub in India, myTomorrows has a truly international presence.

What will new funding bring?

Investment details

Closing in October 2025, this €25 million funding round is pivotal moment and an exciting step toward our mission to fix a broken access system. Avego Healthcare Capital Fund II L.P. brings deep expertise and a powerful network in life sciences, clinical development, and access. Avego invests in private and public companies responsible for developing and commercializing innovative products and services for patients, providers, and other stakeholders across the healthcare continuum.

Use of funds

We are scaling our impact and cement our role as the global authority for pre-approval access by:

• Expanding our global reach, building on our presence in 134+ countries to become the definitive access platform used internationally.
• Advancing our technology, enhancing our widely recognized AI-powered platform to make finding pre-approval treatments faster, smarter, and more efficient.
• Strengthening BioPharma partnerships, deepening collaborations to optimize recruitment and streamline expanded access.
• Growing our real-world data capabilities, turning early access programs into valuable sources of evidence for regulators and developers.
• Supercharging end-to-end patient support, from education to access to follow-up; making their journey as smooth as possible.

Where we are headed next

Building on momentum

We are becoming the default global gateway for all pre-approval treatments – the first destination for patients, caregivers, and physicians when standard options have run out, or when exploring every possible path forward.

Our platform is already recognized for making treatment access faster and more transparent. It’s now evolving into the most complete, trusted and time-saving resource for emerging treatment access, empowering all stakeholders to make informed decisions with speed and confidence.

This transformation is unfolding alongside a broader global shift. Healthcare is becoming more data-driven and patient-centred. New regulatory pathways opening to enable earlier access. Our platform is seamlessly integrated into this evolving landscape, – where innovation, access and evidence converge. myTomorrows stands at the center of this movement, connecting innovation and access on a global scale.

Shaping the future of access

This growth equity round marks more than a financial milestone; it validates our vision to transform how the world connects to pre-approval treatments.

From our founding story to becoming a global access platform, we have built the foundation: trusted partnerships, regulatory excellence, advanced technology, and a determined team. With this investment, we now enter our next chapter, scaling our platform, expanding globally, and deepening industry collaborations.

Together, we are shaping a future where access is no longer an afterthought but a core part of drug development. With the right people, technology, and vision, myTomorrows is ready to set a new standard for how emerging treatments reach the patients who need them most.